PIK-75

• UNSPSC Description:

  PIK-75 is a reversible DNA-PK and p110α-selective inhibitor, which inhibits DNA-PK, p110α and p110γ with IC50s of 2, 5.8 and 76 nM, respectively. PIK-75 inhibits p110α >200-fold more potently than p110β (IC50=1.3 μM)[1][2]. PIK-75 induces apoptosis[3].

• Target Antigen:

  Apoptosis; DNA-PK; PI3K

• Type:

  Reference compound

• Related Pathways:

  Apoptosis;Cell Cycle/DNA Damage;PI3K/Akt/mTOR

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/pik-75-1.html

• Purity:

  99.94

• Solubility:

  DMSO : 13 mg/mL (ultrasonic;warming;heat to 60°C)

• Smiles:

  O=S(C1=CC([N+]([O-])=O)=CC=C1C)(N(C)/N=C/C2=CN=C3C=CC(Br)=CN32)=O

• Molecular Weight:

  452.28

• References & Citations:

  [1]Knight ZA, et al. A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell. 2006 May 19;125(4):733-47.|[2]Chaussade C, et al. Evidence for functional redundancy of class IA PI3K isoforms in insulin signalling. Biochem J. 2007 Jun 15;404(3):449-58.|[3]Duong HQ, et al. Inhibition of NRF2 by PIK-75 augments sensitivity of pancreatic cancer cells to gemcitabine. Int J Oncol. 2014 Mar;44(3):959-69.Adv Sci (Weinh). 2024 Jun 3:e2400023.|Molecules. 2020 Apr 23;25(8):1980.|Clin Cancer Res. 2020 Apr 15;26(8):2011-2021. |Research Square Preprint. 2023 Apr 6.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, protect from light)

• Clinical Information:

  No Development Reported

• CAS Number:

  372196-67-3